HHS Releases Additional $487 Million to States, Territories to Expand Access to Effective Opioid Treatment; 2019 SOR Grants Will Total $1.4 Billion

 

This funding will expand access to treatment that works, especially to medication-assisted treatment (MAT) with appropriate social supports.

Continue reading
Topics:

Aegis Science Corporation Presents Corporate Showcase at AAPM35

View the 30-minute webinar : Are drug interactions harming your patients? Enhance DDI identification and patient care with Interact Rx™ Presented by Josh Schrecker, Pharm.D., Clinical Scientist, Healthcare Services, Aegi...
Continue reading
Topics:
DDI

Loratadine for Improvement of Bone Pain in Patients with Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of loratadine for chronic bone pain in patients with chronic G-CSF use.

Continue reading

PCSS Discussion Forum: A Quick, Evidence-Based Resource from Clinical Experts

The PCSS Discussion Forum provides the opportunity for health professionals to discuss clinical practices around substance use disorders and opioid use disorder with colleagues and addiction and pain experts. (Sign up is required.) 

Continue reading
Topics:

A Clinical Overview of Off-label Use of Gabapentinoid Drugs

The gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain. For gabapentin, the only pain-related indication approved by the US Food and Drug Administration (FDA) is postherpetic neuralgia. For pregabalin, FDA-approved indications related to pain are limited to postherpetic neuralgia, neuropathic pain associated with diabetic neuropathy or spinal cord injury, and fibromyalgia.

Continue reading

Medications to Treat Opioid Addiction Are Effective and Save Lives, But Barriers Prevent Broad Access and Use, Says New Report

A new report from the National Academies of Sciences, Engineering and Medicine, Medications for Opioid Use Disorder Save Lives , says that withholding or failing to have available medications for the treatment of OUD in ...
Continue reading
Topics:

AHRQ Seeks Input on Headaches in Pregnancy and Acute Pain

The Agency for Healthcare Research and Quality (AHRQ) has posted key questions for the systematic review on Management of Primary Headaches in Pregnancy for comment through April 11, as well as a draft technical brief on...
Continue reading

Opioid Treatment Agreement and Prescription Drug Monitoring Program-New Bonus Points for MIPS

Two new bonus measures have been added to the Promoting Interoperability (PI) category in the MIPS (Merit-Based Incentive Payment System) program for 2019. The new measures are not required and do not contribute to the m...
Continue reading
Topics:

AAPM Comments on HHS Pain Management Best Practices Inter-Agency Task Force Draft Report

Comments from the American Academy of Pain Medicine (Docket HHS-OS-2018-0027-0001)

The American Academy of Pain Medicine (AAPM) wishes thank the HHS Pain Management Best Practices Inter-Agency Task Force for their dedication and efforts to improve pain care nationally. The document has been thoroughly reviewed by two major committees within AAPM: the Scientific Review and Guidelines Committee and the Behavioral Medicine Committee.

The emphasis on patient-centered and individualized care is appropriate, and special attention to particularly disadvantaged populations and often neglected populations such as children, adolescents, and older adults is appreciated.

A common theme throughout the HHS document is the inclusion of nearly all available options of treatments within a particular category with relative equal emphasis. While this approach provides a comprehensive review of the subjects, it is important to consistently acknowledge the level of evidence supporting any included therapies, as is the standard practice for the publishing of Practice Guidelines.

We provide below several key concerns and recommendations to improve the document and to better align its content with the biospsychosocial model of pain care and current evidence. We urge these recommendations be considered to improve the content of national policy and training needs for providers as well as information available for those who suffer chronic pain.

Continue reading

AAPM Commitment Statement on Countering the U.S. Opioid Epidemic

The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the increasing toll of the harms that can arise from opioid use disorder. As a...
Continue reading
Topics: